Healthcare -
Biotechnology - NASDAQ - US
$ 0.1948
3.34 %
$ 5.1 M
Market Cap
-0.06
P/E
1. INTRINSIC VALUE
2. FUNDAMENTAL
ANALYSIS
Price Chart PCSA
FINANCIALS
Balance Sheet
Processa Pharmaceuticals, Inc.
| Current Assets | 1.87 M |
| Cash & Short-Term Investments | 1.19 M |
| Receivables | 0 |
| Other Current Assets | 682 K |
| Non-Current Assets | 1.27 M |
| Long-Term Investments | 0 |
| PP&E | 75.7 K |
| Other Non-Current Assets | 1.2 M |
| Current Liabilities | 1.53 M |
| Accounts Payable | 881 K |
| Short-Term Debt | 73 K |
| Other Current Liabilities | 579 K |
| Non-Current Liabilities | 487 |
| Long-Term Debt | 487 |
| Other Non-Current Liabilities | 0 |
EFFICIENCY
Earnings Waterfall
Processa Pharmaceuticals, Inc.
| Revenue | 0 |
| Cost Of Revenue | 0 |
| Gross Profit | 0 |
| Operating Expenses | 12.1 M |
| Operating Income | -12.1 M |
| Other Expenses | -201 K |
| Net Income | -11.9 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Processa Pharmaceuticals, Inc.
| Net Income | -11.9 M |
| Depreciation & Amortization | 782 |
| Capital Expenditures | -3.24 K |
| Stock-Based Compensation | 630 K |
| Change in Working Capital | -112 K |
| Others | -594 K |
| Free Cash Flow | -11.2 M |
Wall Street Analysts Price Targets
Processa Pharmaceuticals, Inc.
PCSA has no price targets from Wall Street.
4. DIVIDEND
ANALYSIS
PCSA does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Processa Pharmaceuticals, Inc.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
213 K USD 4
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Processa Pharmaceuticals Provides Portfolio and Business Update
Signed binding term sheet granting Intact Therapeutics an exclusive option to license PCS12852 Continue enrolling patients in Phase 2 study of PCS6422 Strengthened balance sheet with $7M capital infusion VERO BEACH, Fla., July 01, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical-stage pharmaceutical company developing next-generation cancer therapies, provides updates on its product pipeline, upcoming milestones and business activities.
globenewswire.com
- 1 week ago
Processa Pharmaceuticals Announces Pricing of $7 Million Public Offering
HANOVER, Md., June 17, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (the “Company”), a clinical-stage pharmaceutical company developing Next Generation Cancer (NGC) therapies, today announced the pricing of a public offering of 28,000,000 shares of common stock (or pre-funded warrants in lieu thereof), together with common warrants to purchase up to 28,000,000 shares of common stock at a combined public offering price of $0.25 per share (or pre-funded warrant in lieu thereof) and associated common warrant. The common warrants will have an exercise price of $0.25 per share, are exercisable upon issuance and will expire five years thereafter. The closing of the offering is expected to occur on or about June 18, 2025, subject to the satisfaction of customary closing conditions.
globenewswire.com
- 3 weeks ago
Processa Pharmaceuticals Signs Binding Term Sheet Granting Intact Therapeutics Exclusive Option to License Phase 2 Gastroparesis Drug Candidate
HANOVER, Md., June 17, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), today announced that it has entered into a binding term sheet with Intact Therapeutics, Inc. (“Intact”) granting Intact the exclusive option to license PCS12852, a best-in-class 5-HT4 receptor agonist with the potential to become a first meaningful treatment for gastroparesis and other gastrointestinal motility disorders.
globenewswire.com
- 3 weeks ago
Processa Pharmaceuticals to Engage Potential Partners and Investors at BIO International Convention 2025
HANOVER, Md., June 13, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical-stage pharmaceutical company developing Next Generation Cancer (NGC) therapies, today announced that members of its executive leadership team will attend and participate in the 2025 BIO International Convention, taking place June 16-19, 2025, in Boston, Massachusetts.
globenewswire.com
- 4 weeks ago
Processa Pharmaceuticals Announces Presentation and Publication of Three Abstracts at 2025 ASCO Annual Meeting
HANOVER, Md., May 30, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical-stage pharmaceutical company focused on developing the next generation cancer therapies with improved efficacy and safety, today announced the acceptance of three abstracts for the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 30 to June 3, 2025, at McCormick Place in Chicago, Illinois. The abstracts highlight Processa's pipeline of Next Generation Cancer (NGC) drug candidates, including PCS6422 (NGC-Cap) and PCS11T (NGC-Iri), showcasing both preclinical and clinical advances.
globenewswire.com
- 1 month ago
Processa Pharmaceuticals' Dr. David Young to Present at World Orphan Drug Congress USA 2025
HANOVER, Md., April 15, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (Processa or the Company), a clinical-stage pharmaceutical company focused on developing the next generation cancer therapies with improved efficacy and safety, today announced that Dr. David Young, Founder and President of Research & Development, has been invited to present at the World Orphan Drug Congress USA 2025.
globenewswire.com
- 2 months ago
Processa Pharmaceuticals to Present at the MedInvest Biotech and Pharma Investor Conference
HANOVER, Md., March 18, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (Processa or the Company), a clinical-stage pharmaceutical company focused on developing the next generation cancer therapies with improved efficacy and safety, today announced its participation in the MedInvest Biotech and Pharma Investor Conference being held March 27-28, 2025, at Cooley's law office in New York City.
globenewswire.com
- 3 months ago
Processa Pharmaceuticals to Present at the 2025 BIO CEO & Investor Conference
HANOVER, Md., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (Processa or the Company), a clinical-stage pharmaceutical company focused on developing the next generation cancer therapies with improved efficacy and safety, today announced its participation in the 2025 BIO CEO & Investor Conference being held February 10-11, 2025, at the New York Marriott Marquis.
globenewswire.com
- 5 months ago
Processa Pharmaceuticals Announces Closing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules
HANOVER, Md, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs with improved efficacy and safety, announces the closing of its previously announced “reasonable best efforts” public offering with participation from the Company's Chief Executive Officer, certain board members, and existing institutional investors of the Company, along with a healthcare focused institutional investor, consisting of 8,050,672 shares of common stock (or pre-funded warrants in lieu thereof) and accompanying Series A warrants to purchase up to 8,050,672 shares of common stock (or pre-funded warrants in lieu thereof) and Series B warrants to purchase up to 4,025,336 shares of common stock at a combined purchase price per share (and accompanying warrants) of $0.615 for the institutional investors and $0.7975 for the Company's Chief Executive Officer and certain board members. The closing occurred on January 29, 2025.
globenewswire.com
- 5 months ago
Processa Pharmaceuticals Announces Pricing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules
HANOVER, MD, Jan. 27, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs with improved efficacy and safety, today announced the pricing of its “reasonable best efforts” public offering with participation from the Company's Chief Executive Officer, certain board members, and existing institutional investors of the Company, along with a healthcare focused institutional investor, consisting of 8,050,672 shares of common stock (or pre-funded warrants in lieu thereof) and accompanying Series A warrants to purchase up to 8,050,672 shares of common stock (or pre-funded warrants in lieu thereof) and Series B warrants to purchase up to 4,025,336 shares of common stock at a combined purchase price per share (and accompanying warrants) of $0.615 for the institutional investors and $0.7975 for the Company's Chief Executive Officer and certain board members.
globenewswire.com
- 5 months ago
Processa Pharmaceuticals Announces First Patient Dosed in Phase 2 Clinical Trial of NGC-Cap in Metastatic Breast Cancer
HANOVER, Md., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (Processa or the Company), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs with improved efficacy and safety, today announced that the first patient has been dosed in a Phase 2 clinical trial evaluating NGC-Cap for the treatment of advanced or metastatic breast cancer.
globenewswire.com
- 9 months ago
Processa Pharmaceuticals to Participate in Investor and Industry Conferences During September
HANOVER, Md., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) announces that management will be participating in the following investor and industry conferences during the month of September:
globenewswire.com
- 10 months ago
8. Profile
Summary
Processa Pharmaceuticals, Inc. PCSA
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 5.1 M
Dividend Yield
0.00%
Description
Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development of drug products for the treatment of patients with unmet medical needs in the United States. Its lead product candidate is PCS499, an oral tablet that is in Phase 2B clinical trials for the treatment of ulcerative and non-ulcerative necrobiosis lipoidica, a chronic disfiguring condition. The company is also developing PCS12852, a novel selective 5-hydroxytryptamine 4 (5-HT4) receptor agonist that is in Phase 2A clinical trials for the treatment of gastroparesis, chronic constipation, constipation-predominant irritable bowel syndrome, and functional dyspepsia; PCS3117, a cytosine analog, which is in Phase 2B clinical trials for the treatment of pancreatic and non-small cell lung cancer; and PCS6422, an oral, potent, selective, and irreversible inhibitor of dihydropyrimidine dehydrogenase that is in Phase 1B clinical trials for treating metastatic colorectal and breast cancer. In addition, it develops PCS11T, an analog of SN38 and irinotecan drug for the treatment of various cancers. The company was incorporated in 2011 and is based in Hanover, Maryland.
Contact
7380 Coca Cola Drive, Hanover, MD, 21076
https://www.processapharmaceuticals.com
IPO
Date
March 7, 2014
Employees
10
Officers
Dr. Steven Cha M.D.
Senior Vice President of Clinical Research
Mr. George K. Ng Esq., J.D.
Chief Executive Officer & Director
Dr. David Young Ph.D., Pharm.D.
Co-Founder, President of Research and Development & Director
Mr. Russell L. Skibsted M.B.A.
Chief Financial Officer
Dr. Sian E. Bigora Ph.D., Pharm.D.
Co-Founder and Chief Development & Regulatory Officer
Mr. Patrick Lin
Co-Founder, Chief Business & Strategy Officer
Ms. Wendy J. Guy
Co-Founder, Chief Administrative Officer & Corporate Secretary